Your AI-Trained Oncology Knowledge Connection!
Stroke and stroke recurrence were associated with increased mortality and a negative impact on health-related quality of life measures in survivors of pediatric cancer.
Using RNA sequencing for individual pediatric cancer cases could more effectively target gene expression in tumors.
Approximately 25% of patients with tumor samples submitted to the Pediatric MATCH program have been matched to an investigational therapy at an interim analysis reported ahead of the ASCO Annual Meeting.
Researchers investigated the risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer.
Results of a study evaluating the safety and efficacy of a promising new agent were presented at ASH 2018.
The percentage of patients with pediatric melanoma is 6-fold to the 28-fold higher when compared with the general population of patients with melanoma.
Six months of maintenance chemotherapy improved OS in children with high-risk rhabdomyosarcoma.
A single infusion of the anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel produced durable remissions in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic lymphoma.
Presence of germline TP53 variants predisposed children to acute lymphoblastic leukemia and was associated with adverse outcomes compared with children who did not have these variants, according to the results of a new study.
Here, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
This video reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.
Integrating genetic risk factors with minimal residual disease improves the accuracy of risk stratification for children with acute lymphoblastic leukemia.
Children whose mothers were occupationally exposed to benzene face a higher risk of leukemia, according to results of a national Swiss cohort study.
The FDA has granted approval for the use of dasatinib (Sprycel) in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase.
Combined analysis of risk factors predicts long-term cardiovascular complications in childhood cancer survivors more accurately than single-factor assessments.
Chromosome 11p15 abnormalities should be suspected among children with adrenocortical tumors even in the absence of phenotypic signs of genetic growth disorders like Beckwith-Wiedemann syndrome (BWS), according to a retrospective study.
A novel risk classification scheme based on expression of 36 micro-RNA samples was able to identify pediatric patients with acute myeloid leukemia at high or low risk of experiencing treatment failure, according to a new analysis.
Children with relapsed or refractory INI1-deficient malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated chordomas tolerated treatment with the investigational drug tazemetostat well, including several responses.
Fertility preservation through sperm banking was underutilized among adolescent males newly diagnosed with cancer, according to the results of a recent observational study. Only about one-half of adolescents surveyed in the study attempted sperm banking.
Characteristics of the diabetic intrauterine environment may promote the development of acute lymphoblastic leukemia in offspring, according to the results of a new study.
A parent’s score on the electronic Psychosocial Assessment Tool following the diagnosis of cancer in a child was predictive of future levels of parental distress, according to the results of a new study.
Children covered by Medicaid when diagnosed with cancer have similar survival rates compared with children with private insurance, according to a new study. Evidence shows a slightly increased risk of cancer death among uninsured children, which may be related to a more advanced stage at diagnosis.
The FDA has approved the first gene therapy available in the United States, tisagenlecleucel (Kymriah), for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Survivors of childhood cancer are less likely than the general population to receive the human papillomavirus (HPV) vaccine, according to a study.
Pediatric patients with ALK-positive anaplastic large cell lymphomas and inflammatory myofibroblastic tumors had strong responses to treatment with crizotinib.
